Italy Probes Alleged Antitrust Deal Over Biosimilar Version Of Eye Drug Lucentis

Did Samsung Bioepis and Biogen choose early US access for their Lucentis biosimilar in exchange for postponing launch in other markets? That’s what Italy’s competition authority believes, as it investigates the biosimilar sponsors and originator companies Genentech and Novartis.